|
|
|
| Clinical Analysis of Thrombolysis before Transportation for PCI in Patients with Acute ST Segment Elevation Myocardial Infarction Complicated with Pulmonary Infection |
| LI Zhe, MING Hui, LI Feng-jie |
| Beijing Luhe Hospital, Capital Medical University, Beijing 101100 |
|
|
|
|
Abstract 【Objective】To investigate the clinical effect of thrombolysis before transporting for PCI in patients with STEMI complicated with pulmonary infection. 【Methods】From January 2016 to December 2018, 200 patients with STEMI and pulmonary infection who were treated by PCI were divided into observation group (n=76, thrombolysis before transport) and control group (n=124, none thrombolysis before transport) according to whether thrombolysis was performed before referral. The changes of left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDd), left ventricular end systolic diameter (LVESD) were observed. The serum levels of procalcitonin (PCT) and C-reactive protein (CRP) were compared before and 7 days after treatment. The patients were followed up for half a year to observe the adverse events of the two groups. 【Results】After treatment, LVEDD and LVESD of the two groups were lower than before treatment, and LVEF was higher than before treatment. LVEDd and LVESD of the observation group were lower than that of the control group, and LVEF was higher than that of the control group, the difference was statistically significant (P<0.05). After treatment, the levels of PCT and CRP in serum of the two groups were lower than that before treatment, and that in the observation group was lower than that in the control group (P<0.05). After 6 months follow-up, the incidence of cardiovascular adverse events in the observation group was 5.26% (4 / 76) lower than that in the control group (14.52%) (18/124), the difference was statistically significant (χ2=4.121,P=0.042<0.05). 【Conclusion】Thrombolysis before transportation for PCI is helpful for the recovery of heart function and the control of pulmonary infection in patients with STEMI complicated with pulmonary infection, and it can reduce the risk of cardiovascular adverse events, which is worthy of clinical reference.
|
|
Received: 24 January 2019
|
|
|
|
|
|
[1] 雷锐,李志.介入治疗对合并糖尿病的老年急性心肌梗死患者心脏功能的影响[J].内蒙古医学杂志,2018,50(4):447-448.
[2] 中华医学会呼吸病学分会.中国成人社区获得性肺炎诊断和治疗指南(2016年版)[J].中华结核和呼吸杂志,2016,39(4):253-279.
[3] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会.急性 ST 段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志,2015,45(5):380-393.
[4] 廖文光.负荷量阿司匹林和硫酸氯吡格雷联合尿激酶溶栓对急性 ST 段抬高型心肌梗死患者的疗效评价 [J].中国医学创新,2016,13(28):38-41.
[5] Basnet S, Kozikowski A, Makaryus AN, et al. Metformin and myocardial injury in patients with diabetes and st-segment elevation myocardial infarction: a propensity score matched analysis[J]. J Am Heart Assoc, 2015, 4(10):e002314.
[6] 韩景艳.溶栓治疗老年急性心肌梗死患者的临床影响因素分析 [J].中国实用医药2018,13(2):29-30.
[7] 黄晖,张国山,马芸芸,等.急诊 PCI 治疗急性心肌梗死患者的预后影响因素分析 [J].宁夏医科大学学报,2017,39(12):1404-1407.
[8] Timmer JR, Hoekstra M, Nijsten MW, et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention[J]. Circulation, 2011, 124(6):704-711.
[9] 梁炯林,曾凡源,黄国柱,等.尿激酶溶栓治疗对急性心肌梗死患者 NT-pro BNP 水平和左心室射血分数的影响 [J].中国实用医药,2017,12(20):57-58. |
|
|
|
2019, Vol. 36 
